SIO News

May 7, 2020  
Home  |   About SIO  |   Join SIO  |   Events  |   IO University Subscribe  |   Archive  |   Advertise
 

 
   NEWS FROM SIO


Support the SIO Community and Renew Today Share on FacebookTwitterShare on LinkedinE-mail article
Now, more than ever, community matters. Through the rapidly evolving healthcare landscape, SIO remains vigilant in supporting its members and serving as their voice within the field of IO.

SIO members comprise some of the greatest minds within IO, who together, represent a broader professional network tasked with revolutionizing the field through idea-sharing, collaboration, and research. And you can join our efforts, again.

Rejoin the SIO and help us achieve our mission of advancing the field of interventional oncology. We’d be honored to serve as your professional home once again. With unparalleled access to fellow IO luminaries from around the world, the latest education and science, vital research grants, and more – SIO connects you to the critical resources necessary to further your own professional knowledge, while propelling the future of cancer care. RENEW TODAY



SIO Perspectives:
Navigating IO Care During COVID-19
Share on FacebookTwitterShare on LinkedinE-mail article
The Society of Interventional Oncology’s mission is to bring together physicians, researchers, and members of the IO community for dialogue and learning. SIO’s newest blog series, SIO Perspectives: Navigating IO Care During COVID-19, aims to do just that. In the series, IO leaders share relevant insights and expertise through a collection of blog posts housed on the SIO website.


   SPONSORED CONTENT

Promoted by BTG Interventional Oncology
 


WEBINAR RECORDING AVAILABLE Share on FacebookTwitterShare on LinkedinE-mail article
If you were not able to attend the April 22nd webinar: Impact to Interventional Oncology during COVID-19 presented by SIO and the Society of Interventional Radiology (SIR), you can now access this webinar online by clicking here.

This webinar discusses the current state of IO practice at institutions, what the recovery process will look like, and how to start phasing back in elective cases.


SIO2020 Conference Recordings Now Available! Share on FacebookTwitterShare on LinkedinE-mail article
Whether you attended SIO2020 and want to look back at your favorite presentations or couldn’t join us in New Orleans and want to experience the content you missed, the SIO2020 On Demand conference proceedings are a great purchase! Session listings include the sub-sessions for each session title and the presenters for each topic. View speaker slides, videos, and pointer movements so you can follow along with the recorded presentations. (Abstract sessions and live cases are not included).

Plus, Conference Recordings are now FREE for SIO members. Join now to enjoy this and other great benefits.

To gain access to SIO2020 On Demand: http://www.sio-central.org/page/conference-proceedings. Please note: You must be logged into your SIO member account to access the recordings.


   TOP NEWS


In vivo flow cytometric evaluation of circulating metastatic pancreatic tumor cells after high-intensity focused ultrasound therapy Share on FacebookTwitterShare on LinkedinE-mail article
Cytometry. Part A: The Journal of the International Society for Analytical Cytology
We examined our hypothesis that high-intensity focused ultrasound (HIFU) treatment of pancreatic ductal adenocarcinoma (PDAC) in nude mice models may lead to an increased occurrence of hematogenous metastasis.  READ MORE


.  PRODUCT SHOWCASE
HEAR FROM YOUR PEERS
Interested in hearing about clinical applications of OsteoCool RF Ablation? A brand new webinar just went live- featuring Clinical Treatment of Osteoid Osteomas. Learn More!

Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation Share on FacebookTwitterShare on LinkedinE-mail article
American Journal of Clinical Oncology
The objective of this study was to compare posttransplant outcomes in patients undergoing bridging locoregional therapy with Y-90 transarterial radioembolization (TARE) based protocol compared with transarterial chemoembolization based protocol for hepatocellular carcinoma prior liver transplantation.  READ MORE

 

 
.  SPONSOR SPOTLIGHT
 
 

 
Iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma: Clinical course and treatment outcomes Share on FacebookTwitterShare on LinkedinE-mail article
Journal of Vascular and Interventional Radiology
To analyze the clinical course and treatment outcomes of patients with iatrogenic arterioportal fistula caused by radiofrequency ablation of hepatocellular carcinoma.  READ MORE


DIRECT your Patients: Is this clinical study right for your patient?
AngioDynamics
During the AHPBA Annual Conference taking place March 4th-8th in Miami Beach, Florida, AngioDynamics will be sponsoring a symposium on DIRECT: a clinical study for stage III pancreatic cancer now enrolling patients. Join David Iannitti, MD and Robert Martin, MD, PhD, in their discussion on patient selection for the clinical study. Visit AngioDIRECT.com to learn more about the study. READ MORE
Promoted by AngioDynamics

Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis Share on FacebookTwitterShare on LinkedinE-mail article
Journal of Cancer Research and Clinical Oncology
Local therapy including surgery or radiotherapy has been reported for the treatment of non-small cell lung cancer with synchronous solitary metastasis, while studies with other local ablative treatment are rare. Here, we summarized our single-center experience of microwave ablation for both primary and metastatic lesions in NSCLC patients with synchronous solitary extracranial metastases.  READ MORE




Locoregional therapy protocols with and without radioembolization for hepatocellular carcinoma as bridge to liver transplantation Share on FacebookTwitterShare on LinkedinE-mail article
American Journal of Clinical Oncology
The objective of this study was to compare posttransplant outcomes in patients undergoing bridging locoregional therapy with Y-90 transarterial radioembolization based protocol compared with transarterial chemoembolization based protocol for hepatocellular carcinoma prior liver transplantation.  READ MORE


Transarterial chemoembolization in a woodchuck model of hepatocellular carcinoma Share on FacebookTwitterShare on LinkedinE-mail article
Journal of Vascular Interventional Radiology
To assess the feasibility of transarterial chemoembolization with drug-eluting embolic (DEE) microspheres in a woodchuck model of hepatocellular carcinoma (HCC).  READ MORE


The emerging role of percutaneous thermal ablation in the treatment of thoracic malignancies Share on FacebookTwitterShare on LinkedinE-mail article
Surgical Technology International
Thoracic malignancies pose a significant public health burden in the United States, with primary lung cancer accounting for nearly 25% of cancer deaths each year. Percutaneous thermal ablation for the treatment of lung cancer has evolved from a novel oncologic strategy in the 1970s.  READ MORE


Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? Share on FacebookTwitterShare on LinkedinE-mail article
Journal of Greatpoland Cancer Center
Limited liver metastases represent a clinical challenge. Surgical approach is the most frequently reported treatment option, however, some patients are not eligible for surgical interventions. Relatively recent technologic advances have permitted the safe use of ablative techniques employed in the cure of hepatic metastases.  READ MORE


Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma Share on FacebookTwitterShare on LinkedinE-mail article
Academic Radiology
The goal of this study was to determine the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization in combination with apatinib administration in patients with advanced hepatocellular carcinoma.  READ MORE


PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer Share on FacebookTwitterShare on LinkedinE-mail article
The Journal of Nuclear Medicine
At diagnosis 22% of colorectal cancer patients have metastases and 50% later develop metastasis. Peptide receptor radionuclide therapy with lutetium-177 (177Lu)-PSMA-617 is employed to treat metastatic prostate cancer.  READ MORE

 

 


IO Insights

Connect with SIO

Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version 


Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Lexi Silverberg, Content Editor, 469-420-2609 | Contribute news

The Society of Interventional Oncology
2025 M Street, NW, Suite 800 | Washington, DC 20036 | 202-367-1164 | Contact Us 

Learn how to add us to your safe sender list so our emails get to your inbox.




7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063